Trastuzumab, a monoclonal antibody used in treating HER2-positive breast cancer, can interfere with the HER2 signaling pathway in cardiomyocytes, which is crucial for cell survival and repair mechanisms. Here, ERBB2 is linked to breast carcinoma.